Topic synthesisDoes GLP-1 receptor agonism reduce cardiovascular events in type 2 diabetes?Gap 1Mechanisms of cardiovascular protection beyond measured risk factorsGap 2Hard outcomes for combination GLP-1 RA and SGLT2 inhibitor therapyGap 3Functional consequences of lean mass reduction during weight loss
Every claim has a source
Findings link to the passage they came from, so you can check them.
AI through OpenRouter
We pick models for cost and quality. Data-retention terms vary by AI provider.
Independent
Not affiliated with the databases it reads. Not medical advice.